[Streptokinase therapy of myocardial infarct dependent on the severity of the disease].
A critical analysis of 14 clinical studies published since 1963 on the fibrinolytic treatment of acute cardiac infarct with streptokinase or urokinase shows that only half of them corresponds to the demands of a controlled clinical trial of therapy. The degree of seriousness of the infarct groups described in the different papers shows considerable fluctuations. The findings on letality are not uniform, there is a distinctive trend towards a reduced letality under streptokinase. It was only in recent studies that the dependence of the results of treatment on the seriousness of the disease were checked by retrospective stratification (Australian study) or by prospective stratification (European co-operative study). According to the findings of the European co-operative study those patients who are selected for the purpose of examination and affected with an infarct of medium degree of seriousness being not older than 12 hours have a significantly reduced six months letality under streptokinase on the conditions of this study.
D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D013300:Streptokinase / Q000627:therapeutic use*
D013300:Streptokinase
Streptokinase-Therapie des Herzinfarktes in Abhängigkeit vom Schweregrad der Krankheit.